Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study (Q38378184)
Jump to navigation
Jump to search
scientific article published on 12 April 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study |
scientific article published on 12 April 2017 |
Statements
1 reference
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study (English)
1 reference
Benoît Trottier
1 reference
Jordan E Lake
1 reference
Ken Logue
1 reference
Cynthia Brinson
1 reference
Lizette Santiago
1 reference
Clare Brennan
1 reference
Justin A Koteff
1 reference
Brian Wynne
1 reference
Judy Hopking
1 reference
Catherine Granier
1 reference
Michael Aboud
1 reference
12 April 2017
1 reference
1 reference
Identifiers
1 reference